The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer

Nature Reviews. Urology
Richard C WalshawAnanya Choudhury

Abstract

An urgent need exists to improve the outcomes of patients with muscle-invasive bladder cancer (MIBC), and especially of those with metastatic disease. Treatments that enhance antitumour immune responses - such as immune-checkpoint inhibition - provide an opportunity to do this. Despite initial success, durable response rates in patients with advanced-stage MIBC treated with novel inhibitory antibodies targeting programmed cell death protein 1 (PD-1) or its endogenous ligand programmed cell death 1 ligand 1 (PD-L1) remain low. Radiotherapy is part of the management of bladder cancer in many patients. Evidence that radiotherapy has immunogenic properties is now available, but radiotherapy-induced immune responses are often negated by immunosuppression within the tumour microenvironment. Anti-PD-1 or anti-PD-L1 antibodies might enhance radiotherapy-induced antitumour immunity. This effect has been demonstrated in preclinical models of bladder cancer, and clinical trials involving this approach are currently recruiting. Combination treatment strategies provide an exciting opportunity for urological oncologists to not only improve the chances of cure in patients undergoing radical treatment for MIBC, but also to increase long-term r...Continue Reading

References

Jul 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerB A Lowe
Apr 29, 1998·Immunology and Cell Biology·R Khanna
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C N SternbergUNKNOWN European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
Jun 13, 2003·Lancet·UNKNOWN Advanced Bladder Cancer Meta-analysis Collaboration
Mar 23, 2004·Annual Review of Immunology·Gavin P DunnRobert D Schreiber
Apr 6, 2005·The Journal of Experimental Medicine·Iris LeeWayne W Hancock
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Dec 6, 2005·Cancer Immunology, Immunotherapy : CII·Koji KonoHideki Fujii
Dec 21, 2005·The Journal of Experimental Medicine·Noelia CasaresGuido Kroemer
Dec 31, 2005·The New England Journal of Medicine·Deborah A ZarinNicholas C Ide
Dec 26, 2006·Nature Medicine·Michel ObeidGuido Kroemer
Jun 15, 2007·Current Opinion in Urology·Donna J Sellers, Neil McKay
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Aug 19, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntHans von der Maase
Oct 23, 2009·The Journal of Urology·Eddie S Y ChanWilliam A Larchian
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter J HoskinMichele I Saunders
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Apr 5, 2011·European Urology·Marko BabjukUNKNOWN European Association of Urology (EAU)
Jun 28, 2011·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Stefan StanglGabriele Multhoff
Sep 21, 2011·The Journal of Experimental Medicine·Mercedes B FuertesThomas F Gajewski
Apr 20, 2012·The New England Journal of Medicine·Nicholas D JamesUNKNOWN BC2001 Investigators
Jun 12, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anurag GuptaMaries van den Broek
Nov 20, 2012·Annual Review of Immunology·Guido KroemerLaurence Zitvogel
Jun 19, 2013·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Amanda EustaceCatharine M L West
Oct 16, 2013·Cancer Letters·Shankar SivaOlga A Martin
Jan 3, 2014·The Journal of Clinical Investigation·Liufu DengYang-Xin Fu
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Feb 5, 2014·Nature Reviews. Urology·Gil Redelman-SidiBernard H Bochner
Jul 19, 2014·Immunity·Roy Noy, Jeffrey W Pollard
Aug 15, 2014·Cancer Immunology Research·Kelly G PaulsonPaul Nghiem

❮ Previous
Next ❯

Citations

Aug 4, 2018·Journal of Cancer Research and Clinical Oncology·Yuan ZhuangGuang Li
Aug 20, 2019·Expert Review of Anticancer Therapy·Li-Qing ZouZheng-Fei Zhu
May 18, 2019·American Society of Clinical Oncology Educational Book·Jeanny B Aragon-ChingEvan Y Yu
Oct 24, 2020·Cancer Immunology, Immunotherapy : CII·Wei Zhang QiangLi
Apr 4, 2021·International Journal of Molecular Sciences·Florus C de JongDan Theodorescu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Nature Reviews. Cancer
Dipti VijayanMark J Smyth
Clinical Oncology : a Journal of the Royal College of Radiologists
R MarshallTim M Illidge
International Immunology
George K Philips, Michael Atkins
© 2022 Meta ULC. All rights reserved